We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Array BioPharma Announces Positive Interim Results for Phase 1 Study of Its HER2 Inhibitor in Cancer Patients

News   Dec 14, 2009

 
Array BioPharma Announces Positive Interim Results for Phase 1 Study of Its HER2 Inhibitor in Cancer Patients
 
 
Advertisement
 

RELATED ARTICLES

Team Synthesizes Safer Nonaddictive Analgesics

News

A team has discovered a new class of drugs, capable of relieving pain and reducing fever without the danger of addiction or damage to the liver or kidneys.

READ MORE

Only 5% of the Spanish Population Found To Have Antibodies to SARS-CoV-2

News

A national seroprevalence study concludes that 5% of the Spanish population has antibodies against SARS-CoV-2, no where near estimates thought to be required for the development of natural herd immunity.

READ MORE

Compounds Target Key Enzyme Halting SARS-CoV-2 Replication

News

Researchers have identified several existing compounds that block replication of the COVID-19 virus (SARS-CoV-2) within human cells grown in the laboratory.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE